Tuesday Mar 28, 2017
7:45 AM - 9:30 AM EDT
Tuesday, March 28, 2017
7:45 a.m. - 9:30 a.m.
101 Main Street - Cloud City room, 14th Floor Cambridge, MA
Free
To an early-stage life science project, leveraging means more than just yields and returns. It can often mean the difference between a successful project and one that never gets to commercialization.
Join ArcPoint Strategy Life Sciences for a roundtable discussion that will examine how to apply the art of leverage to your organization and help navigate a project through tough obstacles ahead. We'll discuss ways to streamline the development process, effectively organize teams, and, of course, interface effectively with investors. You'll hear how the Strategic Alliances team at the Novartis Institutes for Biomedical Research has been able to effectively advance technology development through their collaborations, and exchange ideas with other experienced life science experts on:
Dr. J. Michael Delmage has over 25 years of experience in the pharmaceutical, biotechnology, and medical-device industries where he has successfully brought promising products to market. Dr. Delmage served as President and CEO at Transvivo Inc., where in just two years he developed and obtained Federal Drug Administration and CE Mark Approvals for the Omni-DL system, a miniaturized portable dialysis system that supports all current acute dialysis treatments, apheresis and Continuous Renal Replacement Therapies. Previously, he worked at Senetek PLC as Chief Technology Officer, overseeing development of the company's aesthetics, medical devices and therapeutics, as well as Santen International, where he was one of three founding executives who built the 500-person pharmaceutical firm.
Printed courtesy of www.cambridgechamber.org/ – Contact the Cambridge Chamber of Commerce for more information.
One Kendall Square, Cambridge, MA 02139 – (617) 876-4100 – ccinfo@cambridgechamber.org